Sustained Viral Response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA as measured by COBAS TaqMan 48™ (<50 IU/mL) at 24 weeks post completion of the 12 or 24 week treatment period. [clinicaltrials_resource:34a7ed630d911de9a9dd1f3cfc11b39b]

Sustained Viral Response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA as measured by COBAS TaqMan 48™ (<50 IU/mL) at 24 weeks post completion of the 12 or 24 week treatment period. [clinicaltrials_resource:34a7ed630d911de9a9dd1f3cfc11b39b]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:34a7ed630d911de9a9dd1f3cfc11b39b
Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 [clinicaltrials:NCT00143000]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Sustained Viral Response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA as measured by COBAS TaqMan 48™ (<50 IU/mL) at 24 weeks post completion of the 12 or 24 week treatment period. [clinicaltrials_resource:34a7ed630d911de9a9dd1f3cfc11b39b]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:34a7ed630d911de9a9dd1f3cfc11b39b
Bio2RDF identifier
34a7ed630d911de9a9dd1f3cfc11b39b
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:34a7ed630d911de9a9dd1f3cfc11b39b
measure [clinicaltrials_vocabulary:measure]
Sustained Viral Response (SVR) ...... 2 or 24 week treatment period.
identifier
clinicaltrials_resource:34a7ed630d911de9a9dd1f3cfc11b39b
title
Sustained Viral Response (SVR) ...... 2 or 24 week treatment period.
@en
inDataset
type
label
Sustained Viral Response (SVR) ...... 7ed630d911de9a9dd1f3cfc11b39b]
@en